secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001493152-26-013622
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce Biosciences reports Q4 2025 net loss of $2.8M, advances PF614 Phase 3 trial
--------------------------------------------------------------------------------

- Cash $4.3M at Dec 31, 2025; net loss for 2025 $10.2M vs $8.0M in 2024.
- R&D expenses rose $3.2M to $10.4M due to clinical programs for PF614 and PF614-MPAR.
- Enrolled first patient in Phase 3 trial (PF614-301) for moderate-to-severe post-surgical pain.
- FDA supports streamlined 505(b)(2) pathway for PF614-MPAR with overdose-protection labeling.
- USPTO allowed new MPAR patent covering composition-of-matter and method-of-use claims through 2042.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315226013622/0001493152-26-013622-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315226013622/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-013622

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer